This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
In both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity blockbuster.
Radiopharmaceuticals specialist Blue Earth Therapeutics Ltd will use a U$76.5m Series A financing to finance Phase II development of its targeted prostate cancer radiopharmaceuticals Lutetium (177-Lu) rhPSMA-10.1 and Actinium (225-Ac) rhPSMA-10.1.
As the first Nordic company seeking Novel Food approval for a mycoprotein ingredient, Finnish Enifer has filed a authorisation application for it brand PEKILO to the EU food watchdog EFSA.
Digital pathology specialist AIgnostics GmbH has topped up its cash position to US$55m with a US$34m Series B financing. The money will be used to optimise the company’s RudolfV Foundation Model and to develop and offer new services for target and biomarker identification selection, particularly in the US pharma market.
Italian obesity gene therapy developer Resalis Therapeutics srl has gained an equity investment from French pharma major Sanofi SA sufficient to finance its miRNA-22 antisense blocker RES-010 through Phase II proof-of-concept.
Belgian UCB SA and British Cancer UK have started a second clinical study within their multi-year partnership to evaluate the safety and tolerable dose of UCB4594 in patients with advanced cancers.
Another strong financing round for Belgian Agomab NV. Sanofi is joining the band wagon of targeting the TGFbeta receptor.
Rentschler Biopharma announces largest single investment in the higher double-digit range at its headquarters in Germany for construction of a new buffer media facility in Laupheim.
Roche drops a third Alzheimer’s candidate this year, leaving a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease.
Biotech firm Nuclera raises $75M to expand its cutting-edge protein discovery system, speeding up breakthroughs in labs worldwide.